SE0200979D0 - New compounds - Google Patents

New compounds

Info

Publication number
SE0200979D0
SE0200979D0 SE0200979A SE0200979A SE0200979D0 SE 0200979 D0 SE0200979 D0 SE 0200979D0 SE 0200979 A SE0200979 A SE 0200979A SE 0200979 A SE0200979 A SE 0200979A SE 0200979 D0 SE0200979 D0 SE 0200979D0
Authority
SE
Sweden
Prior art keywords
new compounds
active compounds
compounds
new
therapy
Prior art date
Application number
SE0200979A
Other languages
English (en)
Swedish (sv)
Inventor
Stefan Berg
Sven Hellberg
Martin Nyloef
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0200979A priority Critical patent/SE0200979D0/xx
Publication of SE0200979D0 publication Critical patent/SE0200979D0/xx
Priority to ARP030100931A priority patent/AR038996A1/es
Priority to TW092106042A priority patent/TWI330081B/zh
Priority to SA03240054A priority patent/SA03240054B1/ar
Priority to MYPI20031117A priority patent/MY144659A/en
Priority to UA20040806742A priority patent/UA79447C2/uk
Priority to PCT/SE2003/000508 priority patent/WO2003082853A1/en
Priority to PL372966A priority patent/PL211096B1/pl
Priority to JP2003580319A priority patent/JP3989444B2/ja
Priority to MXPA04009163A priority patent/MXPA04009163A/es
Priority to SI200331526T priority patent/SI1492785T1/sl
Priority to BR0308196-6A priority patent/BR0308196A/pt
Priority to IL16389403A priority patent/IL163894A0/xx
Priority to RU2004125146/04A priority patent/RU2338742C2/ru
Priority to ES03745498T priority patent/ES2316784T3/es
Priority to CNB038073897A priority patent/CN100519550C/zh
Priority to CA2476343A priority patent/CA2476343C/en
Priority to KR1020047015389A priority patent/KR101014525B1/ko
Priority to DK03745498T priority patent/DK1492785T3/da
Priority to NZ534664A priority patent/NZ534664A/en
Priority to AU2003216026A priority patent/AU2003216026B2/en
Priority to AT03745498T priority patent/ATE416171T1/de
Priority to CNA2006101537141A priority patent/CN1923812A/zh
Priority to EP08157461A priority patent/EP1961748A3/en
Priority to US10/509,268 priority patent/US7399780B2/en
Priority to EP03745498A priority patent/EP1492785B9/en
Priority to UY27740A priority patent/UY27740A1/es
Priority to PT03745498T priority patent/PT1492785E/pt
Priority to DE60325032T priority patent/DE60325032D1/de
Priority to IL163894A priority patent/IL163894A/en
Priority to ZA200407665A priority patent/ZA200407665B/en
Priority to IS7471A priority patent/IS7471A/is
Priority to NO20044432A priority patent/NO329884B1/no
Priority to HK05104104.0A priority patent/HK1071360A1/xx
Priority to JP2007155810A priority patent/JP2007224051A/ja
Priority to US12/140,510 priority patent/US20090149460A1/en
Priority to CY20091100196T priority patent/CY1108823T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Rheumatology (AREA)
SE0200979A 2002-03-28 2002-03-28 New compounds SE0200979D0 (sv)

Priority Applications (37)

Application Number Priority Date Filing Date Title
SE0200979A SE0200979D0 (sv) 2002-03-28 2002-03-28 New compounds
ARP030100931A AR038996A1 (es) 2002-03-28 2003-03-17 Compuestos con efecto inhibidor sobre la gsk3, formulaciones farmaceuticas que los contienen y proceso de preparacion de los mismos
TW092106042A TWI330081B (en) 2002-03-28 2003-03-19 New compounds, their preparations and their use in treatment and/or prevention of disease associated with glycogen synthase kinase-3
SA03240054A SA03240054B1 (ar) 2002-03-28 2003-03-26 مشتقات 2-هيدروكسي- 3-يترواريل اندول كمثبطات لـ gsk3
MYPI20031117A MY144659A (en) 2002-03-28 2003-03-26 2-hydroxy-3-heteroarylindole derivatives as gsk3 inhibitors
DE60325032T DE60325032D1 (de) 2002-03-28 2003-03-28 2-hydroxy-3-heteroarylindole derivate als gsk3 inhibitoren
CA2476343A CA2476343C (en) 2002-03-28 2003-03-28 2-hydroxy-3-heteroarylindole derivatives as gsk3 inhibitors
AU2003216026A AU2003216026B2 (en) 2002-03-28 2003-03-28 New compounds
PL372966A PL211096B1 (pl) 2002-03-28 2003-03-28 Pochodne indolu, środek farmaceutyczny, zastosowanie pochodnych indolu i związki pośrednie
JP2003580319A JP3989444B2 (ja) 2002-03-28 2003-03-28 新規な化合物
MXPA04009163A MXPA04009163A (es) 2002-03-28 2003-03-28 Nuevos compuestos.
SI200331526T SI1492785T1 (sl) 2002-03-28 2003-03-28 2-hidroksi-3-heteroarilindolni derivati kot inhibitorji GSK3
BR0308196-6A BR0308196A (pt) 2002-03-28 2003-03-28 Composto, formulação farmacêutica, uso de um composto, métodos de prevenção e/ou tratamento de condições associadas com a glicogênio sintase cinase-3, e de doenças, e, processo para a preparação de um composto
IL16389403A IL163894A0 (en) 2002-03-28 2003-03-28 New compounds
RU2004125146/04A RU2338742C2 (ru) 2002-03-28 2003-03-28 Производные индола, способ их получения (варианты), промежуточные соединения, используемые для их получения, фармацевтическая композиция содержащая их и их применение для лечения состояний, связанных с гликоген-синтазой-киназой-3
ES03745498T ES2316784T3 (es) 2002-03-28 2003-03-28 Derivados de 2-hidroxi-3-heteroarilindol como inhibidores de gsk3.
CNB038073897A CN100519550C (zh) 2002-03-28 2003-03-28 具有抑制糖原合成酶激酶3受体作用的2-氧代吲哚化合物
UA20040806742A UA79447C2 (en) 2002-03-28 2003-03-28 Indole derivates, pharmaceutical composition based thereon, process for their preparation (variants), intermediate compound
KR1020047015389A KR101014525B1 (ko) 2002-03-28 2003-03-28 신규 화합물
DK03745498T DK1492785T3 (da) 2002-03-28 2003-03-28 2-hydroxy-3-heteroarylindol-derivater som GSK3-inhibitorer
NZ534664A NZ534664A (en) 2002-03-28 2003-03-28 GSK-3 inhibiting compounds
PCT/SE2003/000508 WO2003082853A1 (en) 2002-03-28 2003-03-28 New compounds
AT03745498T ATE416171T1 (de) 2002-03-28 2003-03-28 2-hydroxy-3-heteroarylindole derivate als gsk3 inhibitoren
CNA2006101537141A CN1923812A (zh) 2002-03-28 2003-03-28 新化合物
EP08157461A EP1961748A3 (en) 2002-03-28 2003-03-28 2-Hydroxy-3-heteroarylindole derivatives as GSK3 inhibitors
US10/509,268 US7399780B2 (en) 2002-03-28 2003-03-28 3-Heterocyclyl-indole inhibitors of glycogen synthase kinase-3
EP03745498A EP1492785B9 (en) 2002-03-28 2003-03-28 2-hydroxy-3-heteroarylindole derivatives as gsk3 inhibitors
UY27740A UY27740A1 (es) 2002-03-28 2003-03-28 Nuevos compuestos
PT03745498T PT1492785E (pt) 2002-03-28 2003-03-28 Derivados de 2-hidroxi-3-heteroarilindole como inibidores de gsk3
IL163894A IL163894A (en) 2002-03-28 2004-09-02 2-hydroxy-3-heteroarylindole derivatives, pharmaceutical compositions comprising them and their uses in the preparation of medicaments
ZA200407665A ZA200407665B (en) 2002-03-28 2004-09-22 New compounds.
IS7471A IS7471A (is) 2002-03-28 2004-09-27 Ný efnasambönd
NO20044432A NO329884B1 (no) 2002-03-28 2004-10-19 Indolderivater, farmasoytisk formulering, anvendelse av forbindelsene, fremgangsmate for fremstilling derav samt mellomprodukter for anvendelse i fremgangsmaten
HK05104104.0A HK1071360A1 (en) 2002-03-28 2005-05-17 2-hydroxy-3-heteroarylindole derivatives as gsk3 inhibitors
JP2007155810A JP2007224051A (ja) 2002-03-28 2007-06-13 新規な化合物
US12/140,510 US20090149460A1 (en) 2002-03-28 2008-06-17 New Compounds
CY20091100196T CY1108823T1 (el) 2002-03-28 2009-02-19 Παραγωγα 2-υδροξυ-3-ετεροαρυλινδολης ως αναστολεις της gsk3

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0200979A SE0200979D0 (sv) 2002-03-28 2002-03-28 New compounds

Publications (1)

Publication Number Publication Date
SE0200979D0 true SE0200979D0 (sv) 2002-03-28

Family

ID=20287447

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0200979A SE0200979D0 (sv) 2002-03-28 2002-03-28 New compounds

Country Status (32)

Country Link
US (2) US7399780B2 (zh)
EP (2) EP1961748A3 (zh)
JP (2) JP3989444B2 (zh)
KR (1) KR101014525B1 (zh)
CN (2) CN1923812A (zh)
AR (1) AR038996A1 (zh)
AT (1) ATE416171T1 (zh)
AU (1) AU2003216026B2 (zh)
BR (1) BR0308196A (zh)
CA (1) CA2476343C (zh)
CY (1) CY1108823T1 (zh)
DE (1) DE60325032D1 (zh)
DK (1) DK1492785T3 (zh)
ES (1) ES2316784T3 (zh)
HK (1) HK1071360A1 (zh)
IL (2) IL163894A0 (zh)
IS (1) IS7471A (zh)
MX (1) MXPA04009163A (zh)
MY (1) MY144659A (zh)
NO (1) NO329884B1 (zh)
NZ (1) NZ534664A (zh)
PL (1) PL211096B1 (zh)
PT (1) PT1492785E (zh)
RU (1) RU2338742C2 (zh)
SA (1) SA03240054B1 (zh)
SE (1) SE0200979D0 (zh)
SI (1) SI1492785T1 (zh)
TW (1) TWI330081B (zh)
UA (1) UA79447C2 (zh)
UY (1) UY27740A1 (zh)
WO (1) WO2003082853A1 (zh)
ZA (1) ZA200407665B (zh)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0302546D0 (sv) * 2003-09-24 2003-09-24 Astrazeneca Ab New compounds
US20040067985A1 (en) * 2002-10-04 2004-04-08 Fortuna Haviv Method of inhibiting angiogenesis
DE602005023333D1 (de) 2004-10-15 2010-10-14 Takeda Pharmaceutical Kinaseinhibitoren
US8046280B2 (en) * 2005-06-10 2011-10-25 Pioneer Hi-Bred International, Inc. Method for using environmental classification to assist in financial management and services
EP1928437A2 (en) 2005-08-26 2008-06-11 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
CA2625153A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
AU2006308889A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
SA07280004B1 (ar) 2006-02-02 2011-10-29 استرازينيكا ايه بي ملح سترات من مركب 2- هيدروكسي –3- [5- (مورفولين –4- يل ميثيل) بيريدين –2- يل] 1h- إندول –5- كربونيتريل سترات
EP1981500A4 (en) * 2006-02-02 2010-08-25 Astrazeneca Ab PHARMACEUTICAL USE OF 2-HYDROXY-3- [5- (MORPHOLIN-4-YLMETHYL) PYRIDINE-2-YL] -1H-INDOL-5-CARBONITRIL AS FREE BASE OR SALT
WO2007089193A1 (en) * 2006-02-02 2007-08-09 Astrazeneca Ab A process for preparing 2-hydroxy-3- [5- (morpholin-4-ylmethyl)pyridin-2-yl] lh-indole-5-carbonitrile as a free base or salts thereof
EP1991539A4 (en) * 2006-02-28 2010-08-25 Astrazeneca Ab NEW SALTS OF INDIGENOUS DERIVATIVES AND THEIR USE IN MEDICINE
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2007120102A1 (en) * 2006-04-19 2007-10-25 Astrazeneca Ab New substituted oxindole derivatives
EP2382975A3 (en) 2006-05-09 2012-02-29 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US20080086340A1 (en) * 2006-10-04 2008-04-10 Pioneer Hi-Bred International, Inc. Crop quality insurance
EA200970361A1 (ru) 2006-10-09 2010-02-26 Такеда Фармасьютикал Компани Лимитед Ингибиторы киназы
BRPI0717618A2 (pt) 2006-10-21 2013-10-22 Abbott Gmbh & Co Kg Compostos heterocíclicos e uso dos mesmos como inibidores de glicogênio sintase quinase 3
WO2008083062A1 (en) 2006-12-29 2008-07-10 Pioneer Hi-Bred International, Inc. Automated location-based information recall
RU2009138136A (ru) 2007-04-18 2011-05-27 Астразенека Аб (Se) Новый способ получения соединения 2-гидрокси-3-[5-(морфолин-4-илметил)пиридин-2-ил]1н-индол-5-карбонитрила 701
EP2183247B1 (en) * 2007-07-30 2012-05-16 AstraZeneca AB New crystalline forms of 2 -hydroxy- 3- [5- (morpholin- 4- ylmethyl) pyridin-2-yl]1h- indole- 5 -carbonitrile citrate
WO2009017453A1 (en) * 2007-07-30 2009-02-05 Astrazeneca Ab New therapeutic combination of an antipsychotic and a gsk3 inhibitor 958
WO2009017455A1 (en) * 2007-07-30 2009-02-05 Astrazeneca Ab A new combination of (a) an alpha-4-beta-2 -neuronal nicotinic agonist and (b) a gsk3 inhibitor
WO2009017454A1 (en) * 2007-07-30 2009-02-05 Astrazeneca Ab New therapeutic combination of a gsk3 inhibitor and an a7-nicotinic agonist 960
CA2736177A1 (en) * 2007-09-06 2009-03-12 Boston Biomedical, Inc. Compositions of kinase inhibitors and their use for treatment of cancer and other diseases related to kinases
US20090291982A1 (en) * 2008-05-22 2009-11-26 Astrazeneca Ab New Substituted Oxindole Derivative 352
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
TW201040191A (en) 2009-03-27 2010-11-16 Abbott Gmbh & Co Kg Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
WO2010143803A2 (en) * 2009-06-08 2010-12-16 Industry Foundation Of Chonnam National University New nicotinamide derivatives with anti-androgen effects, processes of preparing, and antiandrogens comprising the same
JP2011178752A (ja) * 2010-03-03 2011-09-15 Nagoya Univ 含窒素複素環化合物及びその製造方法
JP5998142B2 (ja) 2010-09-27 2016-09-28 アボット ゲーエムベーハー ウント カンパニー カーゲー 複素環化合物およびグリコーゲンシンターゼキナーゼ−３阻害薬としてのその使用
AU2011338389A1 (en) 2010-12-09 2013-06-13 Amgen Inc. Bicyclic compounds as Pim inhibitors
US8962828B2 (en) 2010-12-21 2015-02-24 Bayer Intellectual Property Gmbh Method for producing triazinyl-substituted oxindoles
US9090592B2 (en) 2010-12-30 2015-07-28 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
EP2688886A1 (en) 2011-03-22 2014-01-29 Amgen Inc. Azole compounds as pim inhibitors
PT3702443T (pt) 2013-03-14 2022-02-17 Massachusetts Inst Technology Composições e métodos para expansão e cultura de células estaminais epiteliais
WO2016008966A1 (en) 2014-07-17 2016-01-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for treating neuromuscular junction-related diseases
US10568883B2 (en) 2014-09-03 2020-02-25 Massachusetts Institute Of Technology Compositions, systems, and methods for generating inner ear hair cells for treatment of hearing loss
WO2016207366A1 (en) 2015-06-26 2016-12-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of viral infections
GB201519573D0 (en) 2015-11-05 2015-12-23 King S College London Combination
JP2019506153A (ja) 2016-01-08 2019-03-07 マサチューセッツ インスティテュート オブ テクノロジー 分化した腸内分泌細胞およびインスリン産生細胞の作製
US11260130B2 (en) 2016-03-02 2022-03-01 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV
US10213511B2 (en) 2016-03-02 2019-02-26 Frequency Therapeutics, Inc. Thermoreversible compositions for administration of therapeutic agents
US10201540B2 (en) 2016-03-02 2019-02-12 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
RU2648820C2 (ru) * 2016-04-14 2018-03-28 Общество с ограниченной ответственностью "Научно-исследовательский центр "Парк активных молекул" Средство, обладающее противоклоногенной активностью в отношении опухолевых клеток человека
CN110392686A (zh) 2016-12-30 2019-10-29 频率治疗公司 1h-吡咯-2,5-二酮化合物以及使用它们来诱导干/祖支持细胞自我更新的方法
CN108440401A (zh) * 2018-04-13 2018-08-24 华东理工大学 5-[(4-乙基哌嗪-1-基)甲基]吡啶-2-胺的制备方法
AU2019321641A1 (en) 2018-08-17 2021-04-15 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by upregulating Jag-1
US11617745B2 (en) 2018-08-17 2023-04-04 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by downregulating FOXO
US20220133740A1 (en) 2019-02-08 2022-05-05 Frequency Therapeutics, Inc. Valproic acid compounds and wnt agonists for treating ear disorders

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ192948A (en) * 1979-03-09 1982-02-23 Ishihara Sangyo Kaisha Preparation of beta-trifuloromethyl-pyridine derivatives directly from beta-picoline
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5565580A (en) * 1994-01-27 1996-10-15 Neurosearch A/S Glutamate Antagonists
BR9506936A (pt) 1994-02-23 1997-09-09 Pfizer Derivados de quinazolina substituídos com 4-heterociclila processos para sua preparaçao e seu uso como agentes anticancerosos
TW574214B (en) 1994-06-08 2004-02-01 Pfizer Corticotropin releasing factor antagonists
GB9707800D0 (en) * 1996-05-06 1997-06-04 Zeneca Ltd Chemical compounds
EP1005470B1 (en) * 1997-08-22 2007-08-01 AstraZeneca AB Oxindolylquinazoline derivatives as angiogenesis inhibitors
CN1161333C (zh) 1998-08-20 2004-08-11 住友制药株式会社 作为生长激素释放剂的2-羟基吲哚衍生物
BR0010482A (pt) * 1999-05-21 2002-04-23 Bristol Myers Squibb Co Inibidores pirrolotriazìnicos de cinases
ATE396978T1 (de) * 1999-10-07 2008-06-15 Amgen Inc Triazin-kinase-hemmer
US6455525B1 (en) 1999-11-04 2002-09-24 Cephalon, Inc. Heterocyclic substituted pyrazolones
EP1136493A1 (en) 2000-03-23 2001-09-26 Sanofi-Synthelabo 2-(Thienopyridinyl)pyrimidone, 2-(furopyridinyl)pyrimidone 2-(isoquinolinyl)pyrimidone, 2-(pyridoindolyl)pyrimidone and 2-(benzofuropyridinyl)pyrimidone derivatives
IL153851A0 (en) * 2000-07-27 2003-07-31 Hoffmann La Roche 3-indolyl-4-phenyl-1h-pyrrole-2,5-dione derivatives as inhibitors of glycogen synthase kinase-3beta
EP1330426A4 (en) 2000-10-13 2005-09-14 Bristol Myers Squibb Co SELECTIVE MAXI-K CALIUM CHANNEL OPENING OPERATORS UNDER CONDITIONS OF HIGH INTRA-CELLULAR CALCIUM CONCENTRATIONS, METHOD AND THEIR USE
SE0104340D0 (sv) 2001-12-20 2001-12-20 Astrazeneca Ab New compounds
SE0104341D0 (sv) 2001-12-20 2001-12-20 Astrazeneca Ab New use
AU2002359162A1 (en) * 2001-12-21 2003-07-15 Astrazeneca Ab Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3
TW200301123A (en) * 2001-12-21 2003-07-01 Astrazeneca Uk Ltd New use
SE0302546D0 (sv) * 2003-09-24 2003-09-24 Astrazeneca Ab New compounds
RU2004135382A (ru) * 2002-06-05 2005-06-27 Янссен Фармацевтика Н.В. (Be) Замещенные пирролины в качестве ингибиторов киназы

Also Published As

Publication number Publication date
US20090149460A1 (en) 2009-06-11
PT1492785E (pt) 2009-02-02
US20050153987A1 (en) 2005-07-14
AU2003216026B2 (en) 2008-12-11
SI1492785T1 (sl) 2009-06-30
CA2476343C (en) 2011-05-03
CN1923812A (zh) 2007-03-07
TWI330081B (en) 2010-09-11
NO20044432L (no) 2004-10-19
PL211096B1 (pl) 2012-04-30
DK1492785T3 (da) 2009-03-02
JP2005526814A (ja) 2005-09-08
PL372966A1 (en) 2005-08-08
EP1492785A1 (en) 2005-01-05
EP1492785B9 (en) 2009-10-21
EP1961748A3 (en) 2009-10-07
AU2003216026A1 (en) 2003-10-13
NZ534664A (en) 2007-06-29
BR0308196A (pt) 2005-01-11
CN100519550C (zh) 2009-07-29
WO2003082853A1 (en) 2003-10-09
KR20040094884A (ko) 2004-11-10
IL163894A (en) 2010-11-30
IS7471A (is) 2004-10-15
AR038996A1 (es) 2005-02-02
ATE416171T1 (de) 2008-12-15
SA03240054B1 (ar) 2009-04-04
RU2004125146A (ru) 2005-06-27
EP1492785B1 (en) 2008-12-03
EP1961748A2 (en) 2008-08-27
MXPA04009163A (es) 2004-12-07
TW200306180A (en) 2003-11-16
DE60325032D1 (de) 2009-01-15
US7399780B2 (en) 2008-07-15
UA79447C2 (en) 2007-06-25
UY27740A1 (es) 2003-10-31
ES2316784T3 (es) 2009-04-16
CA2476343A1 (en) 2003-10-09
JP3989444B2 (ja) 2007-10-10
RU2338742C2 (ru) 2008-11-20
WO2003082853A8 (en) 2004-05-06
KR101014525B1 (ko) 2011-02-14
JP2007224051A (ja) 2007-09-06
ZA200407665B (en) 2005-08-29
HK1071360A1 (en) 2005-07-15
IL163894A0 (en) 2005-12-18
MY144659A (en) 2011-10-31
NO329884B1 (no) 2011-01-17
CY1108823T1 (el) 2014-04-09
CN1642938A (zh) 2005-07-20

Similar Documents

Publication Publication Date Title
SE0200979D0 (sv) New compounds
SE0100569D0 (sv) New compounds
TW200510375A (en) New compounds
TW200745111A (en) New compounds
TW200606164A (en) New compounds
EA200300776A1 (ru) Производные фенэтаноламина для лечения респираторных заболеваний
SE0102439D0 (sv) New compounds
PA8591701A1 (es) Derivados de pirrolopirimidina
ATE381537T1 (de) Formanilid-derivative als beta2-adrenorezeptor- agonisten
SE9904508D0 (sv) New compounds
EA200501849A1 (ru) Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ
UY27368A1 (es) Nuevos compuestos
SE0301446D0 (sv) New Compounds
CY1109366T1 (el) Υποκατεστημενες ενωσεις 1,4,8-τριαζασπειρο[4.5]δεκαν-2-ονης
TW200800984A (en) New compounds
MX2009010165A (es) Nuevas imidazo[4,5-b]piridina-7-carboxamidas 704.
TW200634001A (en) Novel compounds
SE0302546D0 (sv) New compounds
SE0102440D0 (sv) New compound
SE0102055D0 (sv) New Compounds
TW200640465A (en) New pharmaceutically active compounds for the treatment of respiratory diseases
SE0102057D0 (sv) New Salts I
IT1307786B1 (it) Analoghi di ceramidi, processo per la loro preparazione e loro usocome antitumorali.
SE0102058D0 (sv) New Salts II
SE0403118D0 (sv) New compounds 2